Connectome-based predictive modeling of brain pathology and cognition in autosomal dominant Alzheimer's disease / Sergio Álvarez Vallejo ; Tripathi, Vaibhav ; Fox Fuller, Joshua ; Malotaux, Vincent ; Baena, Ana Y ; Bonillas Felix, Nikole ; Aguillon, David Fernando ; Lopera, Francisco ; Somers, David C.  

Público ISBD Título : Connectome-based predictive modeling of brain pathology and cognition in autosomal dominant Alzheimer's disease Tipo de documento : texto impreso Autores : Sergio Álvarez Vallejo, Autor ; Tripathi, Vaibhav, Autor ; Fox Fuller, Joshua, Autor ; Malotaux, Vincent, Autor ; Baena, Ana Y, Autor ; Bonillas Felix, Nikole, Autor ; Aguillon, David Fernando, Autor ; Lopera, Francisco, Autor ; Somers, David C., Autor Fecha de publicación : 2025 Títulos uniformes : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : ADAD  CPM  rsfMRI  predictive modeling Resumen : INTRODUCTION: Autosomal dominant Alzheimer's disease (ADAD) through genetic mutations can result in near complete expression of the disease. Tracking AD pathology development in an ADAD cohort of Presenilin-1 (PSEN1) E280A carriers’ mutation has allowed us to observe incipient tau tangles accumulation as early as 6 years prior to symptom onset. METHODS: Resting-state functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) scans were acquired in a group of PSEN1 carriers (n = 32) and non-carrier family members (n = 35). We applied connectome-based predictive modeling (CPM) to examine the relationship between the participant's functional connectome and their respective tau/amyloid-? levels and cognitive scores (word list recall). RESULTS: CPM models strongly predicted tau concentrations and cognitive scores within the carrier group. The connectivity patterns between the temporal cortex, default mode network, and other memory networks were the most informative of tau burden. DISCUSSION: These results indicate that resting-state functional magnetic resonance imaging (fMRI) methods can complement PET methods in early detection and monitoring of disease progression in ADAD. Highlights: Connectivity-based predictive modeling of tau and amyloid-? in ADAD carriers. Strong predictions for tau deposition; weaker predictions for amyloid-?. Cognitive scores for memory and mental state are predicted strongly. Connectivity between IPL, DAN, DMN, temporal cortex most predictive. © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. Mención de responsabilidad : Vaibhav Tripathi, Joshua Fox-Fuller, Vincent Malotaux, Ana Baena, Nikole Bonillas Felix, Sergio Alvarez, David Aguillon, Francisco Lopera, David C. Somers, Yakeel T. Quiroz Referencia : Alzheimer’s Dement. 2025;21:e70061. DOI (Digital Object Identifier) : 10.1002/alz.70061 Derechos de uso : CC BY-NC-ND En línea : https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70061 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Connectome-based predictive modeling of brain pathology and cognition in autosomal dominant Alzheimer's disease [texto impreso] / Sergio Álvarez Vallejo, Autor ; Tripathi, Vaibhav, Autor ; Fox Fuller, Joshua, Autor ; Malotaux, Vincent, Autor ; Baena, Ana Y, Autor ; Bonillas Felix, Nikole, Autor ; Aguillon, David Fernando, Autor ; Lopera, Francisco, Autor ; Somers, David C., Autor . - 2025. Obra : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : ADAD  CPM  rsfMRI  predictive modeling Resumen : INTRODUCTION: Autosomal dominant Alzheimer's disease (ADAD) through genetic mutations can result in near complete expression of the disease. Tracking AD pathology development in an ADAD cohort of Presenilin-1 (PSEN1) E280A carriers’ mutation has allowed us to observe incipient tau tangles accumulation as early as 6 years prior to symptom onset. METHODS: Resting-state functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) scans were acquired in a group of PSEN1 carriers (n = 32) and non-carrier family members (n = 35). We applied connectome-based predictive modeling (CPM) to examine the relationship between the participant's functional connectome and their respective tau/amyloid-? levels and cognitive scores (word list recall). RESULTS: CPM models strongly predicted tau concentrations and cognitive scores within the carrier group. The connectivity patterns between the temporal cortex, default mode network, and other memory networks were the most informative of tau burden. DISCUSSION: These results indicate that resting-state functional magnetic resonance imaging (fMRI) methods can complement PET methods in early detection and monitoring of disease progression in ADAD. Highlights: Connectivity-based predictive modeling of tau and amyloid-? in ADAD carriers. Strong predictions for tau deposition; weaker predictions for amyloid-?. Cognitive scores for memory and mental state are predicted strongly. Connectivity between IPL, DAN, DMN, temporal cortex most predictive. © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. Mención de responsabilidad : Vaibhav Tripathi, Joshua Fox-Fuller, Vincent Malotaux, Ana Baena, Nikole Bonillas Felix, Sergio Alvarez, David Aguillon, Francisco Lopera, David C. Somers, Yakeel T. Quiroz Referencia : Alzheimer’s Dement. 2025;21:e70061. DOI (Digital Object Identifier) : 10.1002/alz.70061 Derechos de uso : CC BY-NC-ND En línea : https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70061 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD002343	AC-2025-026	Archivo digital	Producción Científica	Artículos científicos	Disponible

A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial / Sergio Álvarez Vallejo    

Público ISBD Título : A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial Tipo de documento : documento electrónico Autores : Sergio Álvarez Vallejo, Fecha de publicación : 2022 Títulos uniformes : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer’s disease  amyloid  antibody  data sharing  magnetic resonance imaging  positron emission tomography  presenilin 1  primary prevention  secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial [documento electrónico] / Sergio Álvarez Vallejo,  . - 2022. Obra : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer’s disease  amyloid  antibody  data sharing  magnetic resonance imaging  positron emission tomography  presenilin 1  primary prevention  secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001948	AC-2022-109	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

AC-2022-109 Adobe Acrobat PDF

Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial / Sergio Álvarez Vallejo  

Público ISBD Título : Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial Tipo de documento : documento electrónico Autores : Sergio Álvarez Vallejo, Fecha de publicación : 2022 Títulos uniformes : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer's disease  autosomal-dominant Alzheimer's disease  cognition  neurodegeneration  pathology  preclinical  sex differences Resumen : Introduction: Females may have greater susceptibility to Alzheimer's disease (AD)-pathology. We examined the effect of sex on pathology, neurodegeneration, and memory in cognitively-unimpaired Presenilin-1 (PSEN1) E280A mutation carriers and non-carriers. Methods: We analyzed baseline data from 167 mutation carriers and 75 non-carriers (ages 30 to 53) from the Alzheimer's Prevention Initiative Autosomal Dominant AD Trial, including florbetapir- and fludeoxyglucose-PET, MRI based hippocampal volume and cognitive testing. Results: Females exhibited better delayed recall than males, controlling for age, precuneus glucose metabolism, and mutation status, although the effect was not significant among PSEN1 mutation carriers only. APOE ε4 did not modify the effect of sex on AD biomarkers and memory. Discussion: Our findings suggest that, among cognitively-unimpaired individuals at genetic risk for autosomal-dominant AD, females may have greater cognitive resilience to AD pathology and neurodegeneration than males. Further investigation of sex-specific differences in autosomal-dominant AD is key to elucidating mechanisms of AD risk and resilience. Mención de responsabilidad : Clara Vila-Castelar, Pierre N. Tariot, Kaycee M. Sink, David Clayton, Jessica B. Langbaum, Ronald G. Thomas, Yinghua Chen, Yi Su, Kewei Chen, Nan Hu, Margarita Giraldo-Chica, Carlos Tobón, Natalia Acosta-Baena, Ernesto Luna, Marisol Londoño, Paula Ospina, Victoria Tirado, Claudia Muñoz, Eliana Henao, Yamile Bocanegra, Sergio Alvarez, Silvia Rios-Romenets, Valentina Ghisays, Dhruman Goradia, Wendy Lee, Ji Luo, Michael H. Malek-Ahmadi, Hillary D. Protas, Francisco Lopera, Eric M. Reiman, Yakeel T. Quiroz, the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov;18(11):2272-2282. DOI (Digital Object Identifier) : 10.1002/alz.12552 PMID : 35103388 En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12552 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial [documento electrónico] / Sergio Álvarez Vallejo,  . - 2022. Obra : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer's disease  autosomal-dominant Alzheimer's disease  cognition  neurodegeneration  pathology  preclinical  sex differences Resumen : Introduction: Females may have greater susceptibility to Alzheimer's disease (AD)-pathology. We examined the effect of sex on pathology, neurodegeneration, and memory in cognitively-unimpaired Presenilin-1 (PSEN1) E280A mutation carriers and non-carriers. Methods: We analyzed baseline data from 167 mutation carriers and 75 non-carriers (ages 30 to 53) from the Alzheimer's Prevention Initiative Autosomal Dominant AD Trial, including florbetapir- and fludeoxyglucose-PET, MRI based hippocampal volume and cognitive testing. Results: Females exhibited better delayed recall than males, controlling for age, precuneus glucose metabolism, and mutation status, although the effect was not significant among PSEN1 mutation carriers only. APOE ε4 did not modify the effect of sex on AD biomarkers and memory. Discussion: Our findings suggest that, among cognitively-unimpaired individuals at genetic risk for autosomal-dominant AD, females may have greater cognitive resilience to AD pathology and neurodegeneration than males. Further investigation of sex-specific differences in autosomal-dominant AD is key to elucidating mechanisms of AD risk and resilience. Mención de responsabilidad : Clara Vila-Castelar, Pierre N. Tariot, Kaycee M. Sink, David Clayton, Jessica B. Langbaum, Ronald G. Thomas, Yinghua Chen, Yi Su, Kewei Chen, Nan Hu, Margarita Giraldo-Chica, Carlos Tobón, Natalia Acosta-Baena, Ernesto Luna, Marisol Londoño, Paula Ospina, Victoria Tirado, Claudia Muñoz, Eliana Henao, Yamile Bocanegra, Sergio Alvarez, Silvia Rios-Romenets, Valentina Ghisays, Dhruman Goradia, Wendy Lee, Ji Luo, Michael H. Malek-Ahmadi, Hillary D. Protas, Francisco Lopera, Eric M. Reiman, Yakeel T. Quiroz, the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov;18(11):2272-2282. DOI (Digital Object Identifier) : 10.1002/alz.12552 PMID : 35103388 En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12552 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001932	AC-2022-093	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 3 / 3) Por página: 25 50 100 200